PHARMACOKINETICS (PK) OF EDOXABAN, A NOVEL ORAL ANTICOAGULANT (NOAC), WHEN DOSED ALONE OR FOLLOWING SWITCHING FROM DABIGATRAN OR RIVAROXABAN.

Trial Profile

PHARMACOKINETICS (PK) OF EDOXABAN, A NOVEL ORAL ANTICOAGULANT (NOAC), WHEN DOSED ALONE OR FOLLOWING SWITCHING FROM DABIGATRAN OR RIVAROXABAN.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2016

At a glance

  • Drugs Edoxaban (Primary) ; Dabigatran etexilate; Rivaroxaban
  • Indications Embolism; Stroke; Venous thromboembolism
  • Focus Pharmacokinetics
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 16 Aug 2016 Results of this and two other studies published in the British Journal of Clinical Pharmacology
    • 23 Nov 2015 Results published in the Clinical Drug Investigation
    • 07 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top